

Completed Library Topics



**SCHIZOPHRENIA
LIBRARY**

COMORBID CONDITIONS

Cardiovascular
Diabetes
Metabolic syndrome
HIV

COURSE AND OUTCOMES

Absconding
Employment
Functional Outcomes
Quality of Life
Psychotic relapse
Relationships

First episode psychosis

Duration of untreated psychosis and relationship with outcomes
Duration of untreated psychosis – general
Outcomes for first episode psychosis

DIAGNOSIS

Assessment tools – first episode psychosis

Early Detection
Quality of Care

FAMILIES

Impact on families

PHYSICAL FEATURES

Function – Cerebral blood flow

Functional Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Positron Emission Tomography

Single-Photon Emission Computed Tomography

Function – Chemical alterations

BDNF
HPA Axis Function
Glutamate
Lipids
Neurometabolites
Nitric Oxide
Vitamin D
S100 proteins

Function – Electrophysiology

Electroencephalography
Eye movement dysfunction
Mismatch Negativity
P50
P300
Magnetoencephalography

Function

Immunological changes
Neurological soft signs
Oxidative stress
Pain sensitivity
Temperature regulation

Structure – congenital anomalies

Dermatoglyphics
Minor Physical Anomalies
Morphometrics

Structure

Brain weight and cell density
Computed Tomography
Diffusion Tensor Imaging
Magnetic Resonance Imaging

November 2011

SCHIZOPHRENIA RESEARCH INSTITUTE

405 Liverpool Street, Darlinghurst, Sydney, NSW 2010, Australia Tel: (02) 9295 8688
Email: library@schizophreniaresearch.org.au Web: www.schizophreniaresearch.org.au

To donate, phone the Institute or visit www.schizophreniaresearch.org.au



Brain regions

Amygdala
Basal ganglia
Cerebellum
Cingulate gyrus
Caudate
Corpus callosum
Default mode networks
Frontal lobe
Hippocampus
Insula
Occipital lobe
Parietal lobe
Temporal lobe
Thalamus
Ventricular system
Whole brain volume

POPULATION PERSPECTIVE

Incidence – general

Worldwide
Spatial variation

Incidence – special populations

Sex differences
Migrant status

Prevalence – general

Worldwide
Spatial variation

Prevalence – special populations

Sex differences
Homeless people
Migrant status

RISK FACTORS AND ANTECEDENTS

All environmental vs. genetic risk

Antecedents

Behavioural disturbances and
psychopathology
Neuromotor dysfunction
Premorbid IQ
Speech and language dysfunction

Environmental risk - Physical environment

Influenza
Toxoplasma gondii
Urban environment
Traumatic brain injury

Environmental risk - Prenatal and perinatal

Latitude/season of birth
Maternal diet
Vitamin D
Maternal infections
Maternal stress
Obstetric complications
Paternal age

Environmental risk – Social environment

Childhood trauma
Ethnicity
Social capital
Socioeconomic status
Substance use

Other Risk Factors

Sex
Migration



Genetic Risk

All environmental vs. genetic risk
General information about genetics
and referral to szgene.org

SIGNS AND SYMPTOMS

Early detection
Negative symptoms

Cognition

All cognition with Symptom
Dimensions
Decision Making
Laterality
Olfactory function
Theory of mind

Physical signs

Dermatoglyphics
Minor Physical Anomalies
Neurological soft signs
Morphometrics

TREATMENT

Pharmaceutical treatments

First generation antipsychotics

All – for first episode schizophrenia
Benperidol
Bromperidol
Chlorpromazine
Fluphenazine
Fluspirilene
Haloperidol
Loxapine
Molindone
Penfluridol

Perazine
Perphenazine
Pimozide
Pipotiazine
Thioridazine
Trifluoperazine
Zuclopenthixol

Second generation antipsychotics

All – for first episode schizophrenia
All – for Ultra High Risk individuals
Amisulpride
Aripiprazole
Clotiapine
Clozapine
Olanzapine
Paliperidone
Quetiapine
Remoxipride
Risperidone
Sertindole
Sulpiride
Ziprasidone
Zotepine

Adjunctive treatments;

All – for Hypersalivation
Analeptics
Anticonvulsants
Anti-craving medications
Anticholinergic medications
Cholinesterase inhibitors
Beta blockers
Benzodiazepines
Essential fatty acids
Herbal
Mood stabilisers
Oestrogen
Promethazine
Serotonin modulators



Testosterone

Alternative treatments;

Anticonvulsants
Essential fatty acids
Benzodiazepines
Mood stabilisers
Herbal
Serotonin modulators

Placebo

Placebo response

Non-Pharmaceutical treatments;

Acupuncture
Electroconvulsive Therapy
Exercise therapy
Transcranial Magnetic Stimulation

Psychosocial treatments;

All - for Ultra High Risk individuals
All – for first episode
schizophrenia/psychosis
All – for insight
All – for treatment non-adherence
All – for dual diagnosis
Art and drama therapy
Dance therapy
Behavioural therapies for
antipsychotic induced weight gain
Case management
Cognitive Behavioural Therapy
Cognitive remediation
Community care
Compliance therapy
Enriched interventions
Family intervention
Group therapy
Integrated care

Monetary incentive
Token economies
Vocational therapies